These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 11461070)
1. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070 [TBL] [Abstract][Full Text] [Related]
2. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Kroon HM; Moncrieff M; Kam PC; Thompson JF Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289 [TBL] [Abstract][Full Text] [Related]
3. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821 [TBL] [Abstract][Full Text] [Related]
4. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771 [TBL] [Abstract][Full Text] [Related]
5. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Kroon HM; Lin DY; Kam PC; Thompson JF Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571 [TBL] [Abstract][Full Text] [Related]
7. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Brady MS; Brown K; Patel A; Fisher C; Marx W Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448 [TBL] [Abstract][Full Text] [Related]
8. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Brady MS; Brown K; Patel A; Fisher C; Marx W Melanoma Res; 2009 Apr; 19(2):106-11. PubMed ID: 19282789 [TBL] [Abstract][Full Text] [Related]
9. Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment? Wu ZY; Smithers BM; Anderson C; Roberts MS Melanoma Res; 2000 Feb; 10(1):47-54. PubMed ID: 10711640 [TBL] [Abstract][Full Text] [Related]
10. Isolated hyperthermic limb perfusion chemotherapy in Merkel cell tumour: a case report. Dawson R; Williams OM; Mansel RE J R Coll Surg Edinb; 1996 Aug; 41(4):255-6. PubMed ID: 8772077 [TBL] [Abstract][Full Text] [Related]
11. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Kroon HM; Moncrieff M; Kam PC; Thompson JF Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706 [TBL] [Abstract][Full Text] [Related]
12. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Moncrieff MD; Kroon HM; Kam PC; Stalley PD; Scolyer RA; Thompson JF Ann Surg Oncol; 2008 Oct; 15(10):2749-56. PubMed ID: 18648882 [TBL] [Abstract][Full Text] [Related]
13. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498 [TBL] [Abstract][Full Text] [Related]
14. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605 [TBL] [Abstract][Full Text] [Related]
15. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Benckhuijsen C; Kroon BB; van Geel AN; Wieberdink J Eur J Surg Oncol; 1988 Apr; 14(2):157-63. PubMed ID: 3360157 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Roberts MS; Wu ZY; Siebert GA; Anissimov YG; Thompson JF; Smithers BM Melanoma Res; 2001 Aug; 11(4):423-31. PubMed ID: 11479432 [TBL] [Abstract][Full Text] [Related]
17. Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma? Huismans AM; Kroon HM; Haydu LE; Kam PC; Thompson JF Ann Surg Oncol; 2012 Sep; 19(9):3050-6. PubMed ID: 22526898 [TBL] [Abstract][Full Text] [Related]
18. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612 [TBL] [Abstract][Full Text] [Related]
19. Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. Kam PC; Thompson JF Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1039-45. PubMed ID: 20604735 [TBL] [Abstract][Full Text] [Related]
20. Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma. Elhassadi E; Egan E; O'sullivan G; Mohamed R Clin Lab Haematol; 2006 Aug; 28(4):279-81. PubMed ID: 16898971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]